269,168 Shares in Evolent Health, Inc. (NYSE:EVH) Bought by Fort Baker Capital Management LP

Fort Baker Capital Management LP purchased a new position in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 269,168 shares of the technology company's stock, valued at approximately $3,028,000. Fort Baker Capital Management LP owned about 0.23% of Evolent Health as of its most recent SEC filing.

Several other large investors have also modified their holdings of EVH. Salem Investment Counselors Inc. raised its stake in shares of Evolent Health by 53.0% during the fourth quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company's stock valued at $3,939,000 after purchasing an additional 121,369 shares during the period. Nordea Investment Management AB raised its position in shares of Evolent Health by 7.0% in the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company's stock valued at $1,469,000 after purchasing an additional 8,552 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of Evolent Health by 90.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company's stock valued at $9,036,000 after buying an additional 380,790 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Evolent Health by 40.8% during the third quarter. Franklin Resources Inc. now owns 909,776 shares of the technology company's stock worth $24,682,000 after buying an additional 263,815 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Evolent Health in the fourth quarter worth $2,542,000.

Evolent Health Stock Performance

Shares of NYSE EVH traded down $0.11 during midday trading on Thursday, reaching $8.84. 743,916 shares of the company traded hands, compared to its average volume of 2,395,613. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -10.79 and a beta of 1.04. The stock has a 50-day moving average price of $9.62 and a 200 day moving average price of $11.34. Evolent Health, Inc. has a 52 week low of $8.35 and a 52 week high of $33.63. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The technology company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). The company had revenue of $483.65 million for the quarter, compared to the consensus estimate of $460.15 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The firm's quarterly revenue was down 24.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 earnings per share. Sell-side analysts anticipate that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Evolent Health

In related news, President Daniel Joseph Mccarthy bought 11,040 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were bought at an average cost of $9.01 per share, with a total value of $99,470.40. Following the completion of the transaction, the president now directly owns 389,004 shares of the company's stock, valued at approximately $3,504,926.04. This trade represents a 2.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Brendan B. Springstubb acquired 5,000 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were bought at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the acquisition, the director now owns 11,842 shares in the company, valued at approximately $103,617.50. This trade represents a 73.08% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 74,000 shares of company stock valued at $666,315. 1.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

EVH has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their price objective on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Truist Financial lowered their price target on Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, April 10th. UBS Group raised their price objective on Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. JPMorgan Chase & Co. decreased their price objective on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a report on Monday, March 10th. Finally, JMP Securities restated a "market outperform" rating and issued a $13.00 price target on shares of Evolent Health in a research report on Monday, April 28th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Evolent Health currently has an average rating of "Buy" and an average target price of $17.79.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.